Home blood test for measuring p-tau217 in Alzheimer’s disease using the Tasso device
Official title: Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Run by Neurogen Biomarking LLC · NCT07701161 · Data updated 2026-11-12
Researchers are testing whether a finger-prick style home blood collection tool can reliably measure p-tau217 for people with Alzheimer's disease, mild cognitive impairment, or amyloid- positive/negative status.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 90 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Neurogen Biomarking LLC Industry-sponsored |
| Drugs / interventions | Donanemab, Lecanemab |
| Locations | 5 sites (Chicago, Illinois and 4 other locations) |
| Status | Recruiting |
| Started | January 13, 2025 |
| Main results expected | March 20, 2026 |
| Study ends | August 1, 2026 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT07701161 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40–90 with Alzheimer’s disease, amyloid PET/CSF-confirmed status, healthy controls, or amyloid-negative non-AD cognitive impairment; ability to complete both Tasso and venipuncture collections; caregiver support available if needed.
✕Probably not a fit
Patients unable to perform or tolerate either home or venipuncture blood collection or without access to the required storage/processing may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares p-tau217 blood levels collected at home with the Tasso device to standard venipuncture in individuals with Alzheimer's disease, those with MCI progressing to dementia, and control groups. It includes participants with confirmed amyloid pathology and healthy controls or amyloidnegative cognitive impairment. The goal is to determine if the Tasso method provides comparable biomarker data to traditional blood draws. Subjects are adults aged 40–90 and must be able to complete both collection methods; caregiver support is allowed if needed. No interventions are being tested beyond biomarker collection methods.
Why it matters
Potential benefit: If successful, the home collection method could make regular biomarker testing for p-tau217 easier and more comfortable for patients.
How similar studies have gone: Biomarker studies using alternate collection methods have shown mixed but promising concordance with standard blood draws in related neurodegenerative biomarkers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed Exclusion Criteria: * Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Where it's running
-
Insigth Hospital and Medical Center Chicago
Chicago, Illinois, United States Recruiting -
Insight Hospital and Medical Center Dearborn
Dearborn, Michigan, United States Active not recruiting -
Insight Institute of Neurology and Neurosurgery
Flint, Michigan, United States Active not recruiting -
Memorial Healthcare Hospital
Owosso, Michigan, United States Active not recruiting -
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States Active not recruiting
Study contacts
- Principal investigator: Rany Aburashed — Insight Health Systems
- Study coordinator: Ansam Eghzawi, MD
- Email: ansam@neurogenbiomarking.com
- Phone: +18109410076
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoustic Stimulation During Sleep for Alzheimer’s Disease
Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.
-
FAME: A Italian test to recognize famous faces and name them
This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.
-
NMS-01 safety test in people with mild to moderate Alzheimer's disease
This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.
-
Choose Myself (Before) Losing Myself
We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.
-
Lecanemab-irmb in Real-World Use for Alzheimer’s Disease
This study tests the safety of lecanemab-irmb in people with Alzheimer’s disease by looking at real-world brain-image changes and related events.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.